A bio-healthcare companyGENEWEL

A bio-healthcare companyGENEWEL
With human-centered technology to open happy future for mankind
Since its establishment in 2000, Genewel has established an unrivaled position in the domestic biomaterials field by developing and launching the best brand wound dressing material “Medifoam” and anti-adhesion agent “Guardix” based on its outstanding technology.
Currently, the company is conducting R&D in areas such as wound dressing, anti-adhesion agents, tissue restoration materials, chronic wound treatment materials, and functional drugs, and is also making efforts to expand its influence into various fields such as high-functional medical devices.
In order to achieve the best brand power in Korea as well as in the world, we are continuously discovering talents and performing social contribution, and doing our best to become a company that faithfully fulfills its roles and responsibilities through ethical management based on transparency and fairness.
In addition, through various industry-academy cooperation and national projects, we are pioneering new possibilities and values, and are focusing on R&D to become a leading company in the field of biomaterials and as well as a global bio company.
PRODUCT INFORMATION
Healthcare
FY 2020Y | FY 2021Y | FY 2022Y | |
---|---|---|---|
Total Assets | 33,822 | 38,149 | 42,260 |
Current assets | 12,586 | 24,094 | 26,157 |
Non-current assets | 21,235 | 14,055 | 16,102 |
Total Liabilities | 6,398 | 8,224 | 7,492 |
Current liabilities | 3,974 | 6,632 | 6,754 |
Non-current liabilities | 2,424 | 1,592 | 737 |
Total Assets | 27,424 | 29,926 | 34,768 |
FY 2020Y | FY 2021Y | FY 2022Y | |
---|---|---|---|
Revenue | 25,899 | 30,321 | 32,496 |
Operating profit | 7,235 | 7,885 | 9,279 |
Net profit | 5,570 | 6,102 | 7,762 |
COPYRIGHT 2021@Genewel.ALL RIGHTS RESERVED.
COPYRIGHT 2021@Genewel.ALL RIGHTS RESERVED.